جامعة المعرفة
المصدر المعتمد للمعلومات البحثية والمخرجات هو قاعدة بيانات سكوبس (Elsevier Scopus) مع تدقيق بيانات الباحثين من عمادة البحث العلمي.

Research outputs

المخرجات البحثية

مقالات ومراجعات وأوراق مؤتمرات وفصول كتب، مفهرسة برقم DOI ومربوطة بباحثي الجامعة.

2 مُخرَج نتائج البحث عن «Algorithm»

مراجعةوصول مفتوح2026

Rifaximin Versus Placebo for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Cureus · مجلد 18 (9) · e116820-e116820

Rifaximin, a minimally absorbed broad-spectrum oral antibiotic, is used to target gut dysbiosis in patients with irritable bowel syndrome (IBS).However, conflicting trial data and methodological heterogeneity necessitate an updated, rigorous synthesis of its efficacy and safety profile.We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing rifaximin with placebo in adult patients with IBS, adhering to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 guidelines.The primary outcome was global symptom relief at the end of the treatment.Data were pooled using inverse-variance random-effects models with Hartung-Knapp-Sidik-Jonkman (HKSJ) adjustment.Evidence robustness was evaluated using prediction intervals (PI), Trial Sequential Analysis (TSA), trim-and-fill algorithms for publication bias, and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology.Nine RCTs (yielding 10 randomized comparisons due to one trial's a priori stratification by small intestinal bacterial overgrowth status) were included in this review.For the primary outcome (eight comparisons, N=2,056), rifaximin significantly improved global symptom relief compared to placebo (RR 1.54, 95% CI 1.13 to 2.11; p=0.014), corresponding to a number needed to treat for benefit (NNTB) of 6.However, statistical heterogeneity was substantial (I 2 =59.5%), and the 95% PI crossed the line of no effect (0.89-2.67).The primary effect lost statistical significance upon the exclusion of high-risk-of-bias trials (RR 1.47, 95% CI 0.95-2.27)and after adjusting for publication bias using the trim-and-fill method (RR 1.37, 95% CI 0.93-2.01).The TSA indicated that the accrued information size remained inconclusive for a conservative 15% relative benefit.Rifaximin demonstrated no statistically detectable difference in adverse events compared to placebo, though this is accompanied by considerable uncertainty (Peto OR 0.89 (95% CI 0.65-1.22)).Rifaximin demonstrates a modest overall benefit for global IBS symptoms and an excellent safety profile; however, the certainty of evidence is very low.The apparent efficacy is highly fragile, driven largely by industry-funded trials, undermined by publication bias, and characterized by wide prediction intervals.Biomarker-guided stratification, such as testing for small intestinal bacterial overgrowth (SIBO), may be required to optimize patient selection in future independent trials.

rifaximinirritable bowel syndromeplacebo comparisonantibiotic therapy
مراجعةوصول مفتوح2026

AI-enabled eye-movement and emerging multimodal frameworks for precision dyslexia screening and reading pattern analysis

Frontiers in Medicine · مجلد 13 · 1847464-1847464

Introduction: Developmental dyslexia refers to a common neurodevelopmental disorder, which impairs the accuracy and fluency of reading, and early identification is vital for initiating timely intervention. Nonetheless, the traditional methods of formal assessment are time- and resource-intensive, which limits their scalability. Machine-learning approaches and eye-tracking technologies provide objective, data-driven solutions for dyslexia screening. This research integrates current evidence on eye-movement-based and emerging multimodal computational methods for dyslexia screening, risk identification, and algorithmic classification during reading tasks. Methods: PubMed, Scopus, Web of Science, and CINAHL were searched systematically to identify studies published between January 2015 and March 2026. Eligible studies included analysis of eye-movement obtained via eye tracking or electrooculography (EOG), with or without predictive modeling. Methodological quality was assessed using JBI, PROBAST, ROBINS-I, and COSMIN tools. Results: = 2). The sample sizes ranged from small experimental cohorts (<20 participants) to larger datasets (>300 participants). In the literature, dyslexic readers were consistently found to exhibit longer fixation durations, increased regression behavior and reduced saccadic efficiency. Machine-learning algorithms using fixation, saccade, scan path, and signal-based features demonstrated classification accuracies ranging from approximately 80 to 95% with some studies reporting values approaching 99% under specific experimental conditions. Discussion: Nevertheless, there was a significant heterogeneity in datasets, feature extraction methods, outcome definitions and validation schemes. Notably, numerous studies used proxy diagnostic labels, small or internally derived datasets, and internal cross-validation, which introduces the risk of overfitting and performance inflation. Explicit multimodal or multi-source modeling was identified in three of 23 studies involving combinations of gaze data with demographic, cognitive, linguistic, VR-bed, text-derived, saliency-map, or CNN-based features. Two additional studies used EOG as an alternative eye-movement signal modality rather than true multi-source fusion. Therefore, the evidence base remains dominated by eye-movement and gaze-derived approaches, while multimodal evidence should be interpreted as emerging and exploratory. Altogether, eye-movement based computational systems are a promising, non-invasive method for scalable dyslexia screening. Systematic review registration: PROSPERO, identifier (RD42061332527).

developmental dyslexiadyslexia screeningeye movementseye tracking